Roche (SWX:ROP) expands ADC pipeline with Hansoh as late-stage trial data impress
FROM THE WIRE · FINANCE.YAHOO.COM
Roche Holding (SWX:ROP) agreed a multi-program Antibody-Drug Conjugate collaboration with Hansoh Pharmaceutical, targeting oncology assets beyond China. The partners plan to co-develop and potentially commercialise a portfolio of ADC candidates, combining Roche platforms with…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA new oncology alliance and positive late-stage data can support confidence in the pipeline of a large pharma group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Roche agreed a multi-program ADC collaboration with Hansoh Pharmaceutical.
- 02The partners plan to co-develop and potentially commercialise the candidates.
- 03Roche reported positive late-stage data for several drugs, including new IgA nephropathy results.
- 04Updates were presented for divarasib and giredestrant.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets